Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis

A. Scaife, D. Miller, D. Spiteri Cornish, S. W. Turner, G. S. Devereux, G. Walsh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims
This study tested inhibitory effects of in vitro Montelukast treatment on nasal airway epithelial cells (AEC) cultured from asthmatic patients treated with Montelukast with and without concomitant allergic rhinitis. We further examined the effect of Montelukast withdrawal in these patients on cytokine release from cultured nasal AEC.

Methods
Nasal AEC were collected by brushings from subjects with a history of stable (no exacerbations or change in medication for ≥1 month) physician confirmed mild/moderate asthma whose asthma symptoms were documented to benefit from Montelukast treatment (NCT01230437). Release of the following mediators by nasal AEC were measured: IL-8, IL-6, IL-10, GM-CSF, RANTES, eotaxin and IFN-γ. Nasal AEC were cultured before and one week after withdrawal of their Montelukast treatment.

Results
Forty two asthmatics were recruited. Nasal AEC were successfully cultured in 17 at the first assessment, 14 at the second assessment and in 10 individuals at both assessments. Nasal AEC release was no different between asthmatics with or without allergic rhinitis. Montelukast significantly suppressed the release of IL-8 (p = 0.016), IL-6 (p = 0.006), RANTES (p = 0.002) and IFN-γ (p = 0.046), in a dose dependent manner in unstimulated cultures but not in those stimulated with IL-1/TNF. Withdrawal of Montelukast treatment, was associated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from subjects with asthma and allergic rhinitis but not with asthma alone.

Conclusions
Montelukast treatment for asthma symptoms reversibly suppresses nasal AEC release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured from subjects with concomitant allergic rhinitis.
Original languageEnglish
Pages (from-to)1859-1865
Number of pages7
JournalRespiratory Medicine
Volume107
Issue number12
Early online date18 Sep 2013
DOIs
Publication statusPublished - Dec 2013

Fingerprint

montelukast
Nose
Epithelial Cells
Chemokine CCL5
Interleukin-8
Asthma
Interleukin-6
Therapeutics
Allergic Rhinitis

Keywords

  • Montelukast
  • airway epithelial cells
  • cytokines
  • chemokines
  • inflammation

Cite this

Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis. / Scaife, A.; Miller, D.; Spiteri Cornish, D.; Turner, S. W.; Devereux, G. S.; Walsh, G.

In: Respiratory Medicine, Vol. 107, No. 12, 12.2013, p. 1859-1865.

Research output: Contribution to journalArticle

@article{00a8e507db12472192c535d5b3331557,
title = "Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis",
abstract = "AimsThis study tested inhibitory effects of in vitro Montelukast treatment on nasal airway epithelial cells (AEC) cultured from asthmatic patients treated with Montelukast with and without concomitant allergic rhinitis. We further examined the effect of Montelukast withdrawal in these patients on cytokine release from cultured nasal AEC.MethodsNasal AEC were collected by brushings from subjects with a history of stable (no exacerbations or change in medication for ≥1 month) physician confirmed mild/moderate asthma whose asthma symptoms were documented to benefit from Montelukast treatment (NCT01230437). Release of the following mediators by nasal AEC were measured: IL-8, IL-6, IL-10, GM-CSF, RANTES, eotaxin and IFN-γ. Nasal AEC were cultured before and one week after withdrawal of their Montelukast treatment.ResultsForty two asthmatics were recruited. Nasal AEC were successfully cultured in 17 at the first assessment, 14 at the second assessment and in 10 individuals at both assessments. Nasal AEC release was no different between asthmatics with or without allergic rhinitis. Montelukast significantly suppressed the release of IL-8 (p = 0.016), IL-6 (p = 0.006), RANTES (p = 0.002) and IFN-γ (p = 0.046), in a dose dependent manner in unstimulated cultures but not in those stimulated with IL-1/TNF. Withdrawal of Montelukast treatment, was associated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from subjects with asthma and allergic rhinitis but not with asthma alone.ConclusionsMontelukast treatment for asthma symptoms reversibly suppresses nasal AEC release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured from subjects with concomitant allergic rhinitis.",
keywords = "Montelukast, airway epithelial cells, cytokines, chemokines, inflammation",
author = "A. Scaife and D. Miller and {Spiteri Cornish}, D. and Turner, {S. W.} and Devereux, {G. S.} and G. Walsh",
year = "2013",
month = "12",
doi = "10.1016/j.rmed.2013.09.006",
language = "English",
volume = "107",
pages = "1859--1865",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis

AU - Scaife, A.

AU - Miller, D.

AU - Spiteri Cornish, D.

AU - Turner, S. W.

AU - Devereux, G. S.

AU - Walsh, G.

PY - 2013/12

Y1 - 2013/12

N2 - AimsThis study tested inhibitory effects of in vitro Montelukast treatment on nasal airway epithelial cells (AEC) cultured from asthmatic patients treated with Montelukast with and without concomitant allergic rhinitis. We further examined the effect of Montelukast withdrawal in these patients on cytokine release from cultured nasal AEC.MethodsNasal AEC were collected by brushings from subjects with a history of stable (no exacerbations or change in medication for ≥1 month) physician confirmed mild/moderate asthma whose asthma symptoms were documented to benefit from Montelukast treatment (NCT01230437). Release of the following mediators by nasal AEC were measured: IL-8, IL-6, IL-10, GM-CSF, RANTES, eotaxin and IFN-γ. Nasal AEC were cultured before and one week after withdrawal of their Montelukast treatment.ResultsForty two asthmatics were recruited. Nasal AEC were successfully cultured in 17 at the first assessment, 14 at the second assessment and in 10 individuals at both assessments. Nasal AEC release was no different between asthmatics with or without allergic rhinitis. Montelukast significantly suppressed the release of IL-8 (p = 0.016), IL-6 (p = 0.006), RANTES (p = 0.002) and IFN-γ (p = 0.046), in a dose dependent manner in unstimulated cultures but not in those stimulated with IL-1/TNF. Withdrawal of Montelukast treatment, was associated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from subjects with asthma and allergic rhinitis but not with asthma alone.ConclusionsMontelukast treatment for asthma symptoms reversibly suppresses nasal AEC release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured from subjects with concomitant allergic rhinitis.

AB - AimsThis study tested inhibitory effects of in vitro Montelukast treatment on nasal airway epithelial cells (AEC) cultured from asthmatic patients treated with Montelukast with and without concomitant allergic rhinitis. We further examined the effect of Montelukast withdrawal in these patients on cytokine release from cultured nasal AEC.MethodsNasal AEC were collected by brushings from subjects with a history of stable (no exacerbations or change in medication for ≥1 month) physician confirmed mild/moderate asthma whose asthma symptoms were documented to benefit from Montelukast treatment (NCT01230437). Release of the following mediators by nasal AEC were measured: IL-8, IL-6, IL-10, GM-CSF, RANTES, eotaxin and IFN-γ. Nasal AEC were cultured before and one week after withdrawal of their Montelukast treatment.ResultsForty two asthmatics were recruited. Nasal AEC were successfully cultured in 17 at the first assessment, 14 at the second assessment and in 10 individuals at both assessments. Nasal AEC release was no different between asthmatics with or without allergic rhinitis. Montelukast significantly suppressed the release of IL-8 (p = 0.016), IL-6 (p = 0.006), RANTES (p = 0.002) and IFN-γ (p = 0.046), in a dose dependent manner in unstimulated cultures but not in those stimulated with IL-1/TNF. Withdrawal of Montelukast treatment, was associated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from subjects with asthma and allergic rhinitis but not with asthma alone.ConclusionsMontelukast treatment for asthma symptoms reversibly suppresses nasal AEC release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured from subjects with concomitant allergic rhinitis.

KW - Montelukast

KW - airway epithelial cells

KW - cytokines

KW - chemokines

KW - inflammation

U2 - 10.1016/j.rmed.2013.09.006

DO - 10.1016/j.rmed.2013.09.006

M3 - Article

VL - 107

SP - 1859

EP - 1865

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 12

ER -